Clinical Trials
5 trialsNCT00590187 2024-06-04
Efficacy Study of Oral Sapacitabine to Treat Acute Myeloid Leukemia in Elderly Patients
Cyclacel Pharmaceuticals, Inc.
Phase 2 Completed
NCT01303796 2022-06-22
SEAMLESS
Cyclacel Pharmaceuticals, Inc.
Phase 3 Completed
NCT00380653 2021-12-13
Safety and Pharmacology Study of Sapacitabine to Treat Advanced Leukemias or Myelodysplastic Syndromes
Cyclacel Pharmaceuticals, Inc.
Phase 1 Completed
NCT01253460 2019-09-06
Sapacitabine, Cyclophosphamide, Rituximab for Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (CLL/SLL) With Deletion (11q22-23)
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT01211457 2019-07-16
Study of Sapacitabine in Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS)
Cyclacel Pharmaceuticals, Inc.
Phase 1/2 Unknown